insulin degludec U-200 Tresiba
Selected indexed studies
- Insulin: Making Sense of Current Options. (Endocrinol Metab Clin North Am, 2016) [PMID:27823608]
- Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine. (J Prim Care Community Health, 2025) [PMID:40162894]
- Long-Acting Basal Insulins: A Review of the More Recently Approved Agents. (Cardiol Rev, 2019) [PMID:31393288]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Insulin: Making Sense of Current Options. (2016) pubmed
- Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine. (2025) pubmed
- Long-Acting Basal Insulins: A Review of the More Recently Approved Agents. (2019) pubmed
- An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Degludec U-100 and U-200. (2016) pubmed